title: A global health partnership's use of time-limited support to catalyze health practice change: the case of GAVI's Injection Safety Support.
abstract: This paper presents the findings of a study to assess the effectiveness and sustainability of a GAVI (Global Alliance of Vaccines and Immunization) sponsored, time-limited Injection Safety (INS) support. The support came in two forms: 1) in-kind, in the form of AD syringes and safety boxes, and 2) in cash, for those countries that already had a secure, multi-year source of AD syringes and safety boxes, but proposed to use INS support to strengthen their injection safety activities. In total, GAVI gave INS support for a three-year period to 58 countries: 46 with commodities and 12 with cash support. To identify variables that might be associated with financial sustainability, frequencies and cross-tabulations were run against various programmatic and socio-economic variables in the 58 countries. All but two of the 46 commodity-recipient countries were able to replace and sustain the use of AD syringes and safety boxes after the end of their GAVI INS support despite the fact that standard disposable syringes are less costly than ADs (10-15 percent differential). In addition, all 12 cash-recipient countries continued to use AD syringes and safety boxes in their immunization programs in the years following GAVI INS assistance. At the same time, countries were often not prepared for the increased waste management requirements associated with the use of the syringes, suggesting the importance of anticipating challenges with the introduction of new technologies. The sustained use of AD syringes in countries receiving injection safety support from GAVI, in a majority of cases through government financing, following the completion of three years of time-limited support, represents an early indication of how GHPs can contribute to improved health outcomes in immunization safety in the world's poorest countries in a sustainable way.
authors.affiliation: annlevin@verizon.net
authors.forename: Ann
authors.initials: A
authors.lastname: Levin
authors.forename: Arnold
authors.initials: A
authors.lastname: Fang
authors.forename: Peter M
authors.initials: PM
authors.lastname: Hansen
authors.forename: David
authors.initials: D
authors.lastname: Pyle
authors.forename: Ousmane
authors.initials: O
authors.lastname: Dia
authors.forename: Nina
authors.initials: N
authors.lastname: Schwalbe
mesh_terms: D005380:Financing, Government / Q000191:economics; D014943:Global Health; D006801:Humans; D007114:Immunization / Q000191:economics* / Q000295:instrumentation*; D017589:Immunization Programs / Q000191:economics* / Q000458:organization & administration / Q000600:supply & distribution*; D007267:Injections; D012449:Safety / Q000191:economics; D013594:Syringes / Q000191:economics; D014612:Vaccines / Q000008:administration & dosage* / Q000191:economics
chemical_list: D014612:Vaccines